UNICHEM LABORATORIES
|
UNICHEM LABORATORIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 19.53 | -13.32 | -28.72 | 4.70 | 4.88 |
| CEPS(Rs) | 37.23 | 4.18 | -12.61 | 17.64 | 16.86 |
| DPS(Rs) | - | - | - | 4.00 | 4.00 |
| Book NAV/Share(Rs) | 347.37 | 345.91 | 344.18 | 370.39 | 362.05 |
| Tax Rate(%) | 11.04 | -10.36 | -14.67 | -50.49 | 33.32 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 12.55 | 4.87 | -3.39 | 5.73 | 7.38 |
| EBIT Margin(%) | 8.32 | -3.49 | -11.84 | 2.21 | 4.58 |
| Pre Tax Margin(%) | 7.32 | -4.76 | -13.13 | 1.73 | 4.17 |
| PAT Margin (%) | 6.51 | -5.25 | -15.06 | 2.60 | 2.78 |
| Cash Profit Margin (%) | 12.42 | 1.65 | -6.61 | 9.78 | 9.61 |
| Performance Ratios | |||||
| ROA(%) | 4.04 | -2.91 | -6.22 | 1.03 | 1.10 |
| ROE(%) | 5.64 | -3.86 | -8.04 | 1.28 | 1.35 |
| ROCE(%) | 6.34 | -2.31 | -5.60 | 1.00 | 2.11 |
| Asset Turnover(x) | 0.62 | 0.55 | 0.41 | 0.40 | 0.40 |
| Sales/Fixed Asset(x) | 1.08 | 0.97 | 0.86 | 0.99 | 1.08 |
| Working Capital/Sales(x) | 2.03 | 1.77 | 1.42 | 1.16 | 1.42 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.93 | 1.03 | 1.17 | 1.01 | 0.93 |
| Receivable days | 122.86 | 125.84 | 147.31 | 107.17 | 94.63 |
| Inventory Days | 149.13 | 139.19 | 166.52 | 163.63 | 138.14 |
| Payable days | 183.16 | 183.72 | 179.25 | 201.09 | 278.03 |
| Valuation Parameters | |||||
| PER(x) | 35.47 | - | - | 55.44 | 63.44 |
| PCE(x) | 18.61 | 116.97 | -22.92 | 14.76 | 18.35 |
| Price/Book(x) | 1.99 | 1.41 | 0.84 | 0.70 | 0.85 |
| Yield(%) | - | - | - | 1.54 | 1.29 |
| EV/Net Sales(x) | 2.46 | 1.96 | 1.60 | 1.61 | 1.78 |
| EV/Core EBITDA(x) | 17.29 | 29.54 | -304.97 | 17.03 | 15.54 |
| EV/EBIT(x) | 29.55 | -56.18 | -13.50 | 73.00 | 38.80 |
| EV/CE(x) | 1.80 | 1.32 | 0.79 | 0.62 | 0.83 |
| M Cap / Sales | 2.31 | 1.93 | 1.52 | 1.44 | 1.76 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 18.25 | 32.92 | 5.76 | 2.81 | 11.91 |
| Core EBITDA Growth(%) | 153.38 | 1,782.74 | -105.85 | -14.86 | 248.94 |
| EBIT Growth(%) | 381.89 | 60.83 | -666.54 | -50.70 | 240.22 |
| PAT Growth(%) | 246.67 | 53.64 | -711.67 | -4.63 | 157.03 |
| EPS Growth(%) | 246.67 | 53.63 | -711.66 | -3.68 | 157.03 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.18 | 0.09 | 0.12 | 0.13 | 0.04 |
| Current Ratio(x) | 2.05 | 2.36 | 2.48 | 2.98 | 2.72 |
| Quick Ratio(x) | 1.05 | 1.37 | 1.51 | 1.89 | 1.66 |
| Interest Cover(x) | 8.35 | -2.75 | -9.19 | 4.60 | 11.06 |
| Total Debt/Mcap(x) | 0.09 | 0.06 | 0.15 | 0.18 | 0.05 |
Compare Financial Ratios of peers of UNICHEM LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| UNICHEM LABORATORIES | ₹4,549.6 Cr | 8% | 9.6% | 12.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹408,091.0 Cr | 2.3% | 3.2% | 9.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹181,302.0 Cr | -0.2% | 4.5% | 49.6% | Stock Analytics | |
| CIPLA | ₹119,038.0 Cr | -0.2% | -2% | -1.4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹117,170.0 Cr | 3.7% | 6.5% | 16.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹105,061.0 Cr | -0% | -4.6% | -6.2% | Stock Analytics | |
UNICHEM LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| UNICHEM LABORATORIES | 8% |
9.6% |
12.9% |
| SENSEX | -1.1% |
1% |
3.4% |
You may also like the below Video Courses
